The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NIVACOR: Phase II study of nivolumab in combination with FOLFOXIRI/bevacizumab in first-line chemotherapy for advanced colorectal cancer RASm/BRAFm patients.
 
Angela Damato
No Relationships to Disclose
 
Francesco Iachetta
No Relationships to Disclose
 
Nicola Normanno
No Relationships to Disclose
 
Francesca Bergamo
No Relationships to Disclose
 
Evaristo Maiello
No Relationships to Disclose
 
Alberto Zaniboni
Consulting or Advisory Role - Amgen; Bayer; Merck Serono; Servier
Speakers' Bureau - servier
 
Lorenzo Antonuzzo
No Relationships to Disclose
 
Guglielmo Nasti
No Relationships to Disclose
 
Giuseppe Tonini
Consulting or Advisory Role - Italfarmaco; Molteni Farmaceutici; Novartis; Pierre Fabre; Roche
Research Funding - Novartis (Inst); PharmaMar (Inst)
 
Roberto Bordonaro
Honoraria - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen-Cilag; Novartis; Pfizer; Roche; Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen-Cilag; Novartis; Pfizer; Roche; Sanofi
Speakers' Bureau - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen-Cilag; Novartis; Pfizer; Roche; Sanofi
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Pfizer; Roche
 
Francesca Di Fabio
No Relationships to Disclose
 
Alessandra Romagnani
No Relationships to Disclose
 
Annalisa Berselli
No Relationships to Disclose
 
Carmine Pinto
No Relationships to Disclose